Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00033111
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
2002-04-05
Brief Title:
A Study of Cabergoline for the Treatment of Cocaine Dependence - 1
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Phase 2 Double-Blind Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence
Detailed Description:
To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence This is a DB placebo-controlled parallel group design study where subjects will receive either 5mg cabergoline or placebo for 12 weeks with a 4 week follow-up
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None